Demographic clinical and prognostic characteristics of primary ovarian, peritoneal and tubal adenocarcinomas of serous histology — A prospective comparative study

Schnack, Tine Henrichsen; Sörensen, R; Nedergaard, Lotte; Høgdall, Claus

doi:10.1016/j.ygyno.2014.08.020

Cited by 16 publications

(56 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PPC patients were found to have a significantly higher age at diagnosis than SPOC patients in seven studies [4,[7][8][9]12,16,17]. Similar trends though not significant were found in three studies [10,18,19].…”

Section: Agesupporting

confidence: 54%

“…Of six studies comparing FC with OC, two found that FC cases had a significantly higher age at diagnosis [4,14] whereas no significant differences were found in the remaining studies [7,17,20,21].…”

Section: Agementioning

confidence: 90%

“…Five studies found, that women with PPC had a higher number of births or termed pregnancies compared to women with OC [4,7,8,10,11], whereas two studies found no difference between PPC and OC cases in this matter [9,12]. One of the studies found a non-significantly increased risk of PPC associated with parity when compared to controls [4].…”

Section: Paritymentioning

confidence: 94%

“…Data on risk factor profiles of PPC vs. OC and FC vs. OC were compared in seven [4,[7][8][9][10][11][12] and five case-control studies [4,7,[13][14][15], respectively (Tables 1a and 1b).…”

Section: Risk Factorsmentioning

confidence: 99%

“…Seven studies [4,[7][8][9][10][11][12] examined the association between being parous, parity or pregnancies and OC vs. PPC. Five studies found, that women with PPC had a higher number of births or termed pregnancies compared to women with OC [4,7,8,10,11], whereas two studies found no difference between PPC and OC cases in this matter [9,12].…”

Section: Paritymentioning

confidence: 99%

See 4 more Smart Citations

Serous ovarian, fallopian tube and primary peritoneal cancers: A common disease or separate entities — A systematic review

Sörensen

Schnack

Karlsen

et al. 2015

Gynecologic Oncology

Self Cite

View full text Add to dashboard Cite

Section: Agesupporting

confidence: 54%

Section: Agementioning

confidence: 90%

Section: Paritymentioning

confidence: 94%

“…Data on risk factor profiles of PPC vs. OC and FC vs. OC were compared in seven [4,[7][8][9][10][11][12] and five case-control studies [4,7,[13][14][15], respectively (Tables 1a and 1b).…”

Section: Risk Factorsmentioning

confidence: 99%

Section: Paritymentioning

confidence: 99%

See 3 more Smart Citations

Serous ovarian, fallopian tube and primary peritoneal cancers: A common disease or separate entities — A systematic review

Sörensen

Schnack

Karlsen

et al. 2015

Gynecologic Oncology

Self Cite

View full text Add to dashboard Cite

Tissue glycomics distinguish tumour sites in women with advanced serous adenocarcinoma

et al. 2017

View full text Add to dashboard Cite

In the era of precision medicine, the tailoring of cancer treatment is increasingly important as we transition from organ‐based diagnosis towards a more comprehensive and patient‐centric molecular diagnosis. This is particularly the case for high‐grade serous adenocarcinomas of the ovary and peritoneum, which are commonly diagnosed at an advanced stage, and collectively treated and managed similarly. We characterized the N‐ and O‐glycome of serous ovarian (OC) and peritoneal cancer (PC) tissues using PGC‐LC‐ESI‐IT‐MS/MS profiling and validated the discriminatory glycans and their corresponding glyco‐gene expression levels using cell lines and transcriptomic data from 232 patients. Overall, the N‐ and O‐glycan repertoires of both cancer types were found to comprise mostly of α2,6‐sialylated glycan structures, with the majority of N‐glycans displaying the biantennary mono‐ and disialylation as well as bisecting‐type biantennary glycans. The MS profiling by PGC‐LC also revealed several glycan structural isomers that corresponded to LacdiNAc‐type (GalNAcβ1‐4GlcNAc) motifs that were unique to the serous ovarian cancers and that correlated with elevated gene expression of B4GALNT3 and B4GALNT4 in patients with serous cancer. Statistical evaluation of the discriminatory glycans also revealed 13 N‐ and 3 O‐glycans (P < 0.05) that significantly discriminated tumour‐sampling sites, with LacdiNAc‐type N‐glycans (m/z 1205.02− and m/z 1059.42−) being associated with ovarian‐derived cancer tissue and bisecting GlcNAc‐type (m/z 994.92−) and branched N‐glycans (m/z 1294.02− and m/z 1148.42−) upregulated at the metastatic sites. Hence, we demonstrate for the first time that OC and PC display distinct molecular signatures at both their glycomic and transcriptomic levels. These signatures may have potential utility for the development of accurate diagnosis and personalized treatments.

show abstract

High‐grade serous peritoneal cancer follows a high stromal response signature and shows worse outcome than ovarian cancer

et al. 2020

View full text Add to dashboard Cite

Serous peritoneal and high‐grade serous ovarian/tubal cancers are treated identically with maximal cytoreductive surgery and platinum‐based chemotherapy. Here, we provide epidemiological, clinical, and molecular evidence that peritoneal cancer is more aggressive and shows a distinct molecular signature on gene and protein levels. Our data suggest alternative treatment decisions and to consider the tumor‐sampling site for diagnosis in the future.

show abstract

Demographic clinical and prognostic characteristics of primary ovarian, peritoneal and tubal adenocarcinomas of serous histology — A prospective comparative study

Cited by 16 publications

References 39 publications

Serous ovarian, fallopian tube and primary peritoneal cancers: A common disease or separate entities — A systematic review

Serous ovarian, fallopian tube and primary peritoneal cancers: A common disease or separate entities — A systematic review

Tissue glycomics distinguish tumour sites in women with advanced serous adenocarcinoma

High‐grade serous peritoneal cancer follows a high stromal response signature and shows worse outcome than ovarian cancer

Contact Info

Product

Resources

About